Translation To Version Management- The EuroQol Experience

Published Feb 17, 2014
Rotterdam, Netherlands - The EuroQol five-dimensional (EQ-5D) questionnaire is used world-wide as a patient-reported outcome (PRO) instrument for the measurement and valuation of health. As the use of EQ-5D has increased exponentially, so has the demand for new variants and formats, and new language versions of the instrument. The EuroQol Group realized the need to implement standardized procedures which ensured EQ-5D versions were produced following international guidelines. Wide experience in translating the instrument has also led to some innovations within the standard translation procedures. The aim of the procedures is to produce versions which are semantically equivalent and which permit comparison and aggregation of data obtained with different language versions. Quality control is ensured through oversight by an experienced team of reviewers. An experienced team ensures high levels of quality control over language versions in different formats. This process results in the production of high-quality translations that allow for the comparison and aggregation of data across countries. In their article, “From Translation to Version Management: A History and Review of Methods for the Cultural Adaptation of the EuroQol Five-Dimensional Questionnaire,” published in Value in Health, the researchers describe the evolution of the production of other language versions of the EQ-5D from the earliest days of simultaneous production and translation of the EQ-5D questionnaire, to the more recent, broader-based strategy of version management. The review describes these changes based on the authors’ own experiences and use of material located at the EuroQol Executive Office in Rotterdam, the Netherlands. The researchers report that, currently, the EQ-5D three-level self-complete version is available in nearly 200 languages, while the five-level version is available in more than 100 languages. The researchers conclude that version management in the case of a widely-used PRO instrument like the EQ-5D requires considerable resources and a well-structured approach to ensure standardisation and quality control. A rigorous and adaptive approach to producing other language versions is essential. For more information on the EuroQol Group, please see: http://www.euroqol.org/euroqol-group/about-us.html

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×